Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- January31 2004
- Volume 11
- Issue 2
Who Knew?
Advertisement
(Health magazine, 2004)
37%—Percentage of physicians whosay medical school didn't preparethem well for their profession.
Articles in this issue
about 18 years ago
Understand the Fully Bundled Pensionsabout 18 years ago
Establish Year-Round Financial Planningabout 18 years ago
Understand the Expenses of Your Childabout 18 years ago
Learn the Secrets of Wilbur and Orvilleabout 18 years ago
Get the New Year Off to an Excellent Startabout 18 years ago
Don't Outlive Your Retirement Nest Eggabout 18 years ago
Portfolio CHECK-UPabout 18 years ago
Does Med School Affect Malpractice?about 18 years ago
With Asset Protection, Compliance Is Keyabout 18 years ago
Read a Pair of Classic Investment TomesAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
Agusti, chair of the GOLD Board of Directors, discusses which COPD diagnostic bottleneck AI is closest to solving and more.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
Advertisement
Advertisement
Trending on HCPLive
1
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
2
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
3
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
4
DAPA-TRIO-HF: Dapagliflozin Improves HF Outcomes Regardless of Healthcare Setting
5